1000005-59-3

Basic information

• Product Name: benzoic acid 4-dimethylamino-2-[14-ethyl-12,13-dihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester
• Synonyms: benzoic acid 4-dimethylamino-2-[14-ethyl-12,13-dihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester
• CAS NO: 1000005-59-3
• Molecular Weight: 852.073
• Mol File: 1000005-59-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: benzoic acid 4-dimethylamino-2-[14-ethyl-12,13-dihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: benzoic acid 4-dimethylamino-2-[14-ethyl-12,13-dihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester(1000005-59-3)
• EPA Substance Registry System: benzoic acid 4-dimethylamino-2-[14-ethyl-12,13-dihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester(1000005-59-3)

Safety Data

• Hazardous Substances Data: 1000005-59-3(Hazardous Substances Data)

Upstream product

• 81103-11-9 clarithromycin 
• 93-97-0 benzoic acid anhydride 

Downstream Products

• 1054665-73-4 C₄₇H₇₇NO₁₈S₂ 
• 190839-65-7 Benzoic acid (2S,3R,4S,6R)-4-dimethylamino-2-((E)-(3R,5R,6R,7R,9R,13S,14R)-14-ethyl-13-hydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,4,10-trioxo-oxacyclotetradec-11-en-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester 
• 676536-47-3 Benzoic acid (2S,3R,4S,6R)-4-dimethylamino-2-((E)-(3R,4S,5S,6R,7R,9R,13S,14R)-14-ethyl-4,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-11-en-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester 
• 1054646-12-6 benzoic acid 4-dimethylamino-2-[14-ethyl-13-hydroxy-4-(5-methanesulfonyloxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-11-en-6-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester 
• 190839-61-3 C₃₇H₅₉NO₁₁ 
• 875475-90-4 C₃₈H₅₇NO₁₂ 
• 760981-83-7 (3aS,4R,7S,9R,10R,11R,13R,15R)-1-(4-(4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl)butyl)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-7-fluoro-11-methoxy-3a,7,9,11,13,15-hexamethyloctahydro-1H-[1]oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(7H,9H)-tetraone 

Relevant articles and documents

Synthesis of 14,15-dehydroerythromycin A ketolides: Effects of the 13-substituent on erythromycin tautomerism

A ketolide was prepared from 14,15-dehydroerythromycin A by two different routes. The first approach involving oxidation of the 3-OH of 3-descladinosyl-14,15-dehydroerythromycin A 2′-O-acetate gave unexpectedly high levels of 3,11-double oxidation. This may be due to greater formation of the 9,12-hemiketal in 14,15-dehydroerythromycin A and concomitant exposure of the 11-OH group for oxidation. NMR studies of 14,15-dehydroerythromycin A support this hypothesis, revealing a 9:1 ratio of 9-ketone to 9,12-hemiketal in CDC13 and a 1:1 ratio in CD3OD as contrasted with the corresponding tautomer ratios of 30:1 in CDC13, and 6: 1 in CD3OD with erythromycin A. Alteration of the 13-substituent on the erythronolide A ring from ethyl to vinyl thus favors formation of the 9,12-hemiketal. A second route to the ketolides was developed based on these findings, in which the 11-OH is eliminated prior to oxidation of the 3-OH.

Method for preparing solithromycin

The invention discloses a novel method for preparing solithromycin. Compared with the conventional solithromycin preparation process, a designed synthesis process adopted by the novel method has the advantages that the occurrences of side reactions are effectively reduced, the dangerous and toxic operating steps are avoided, and the reaction conversion rate is improved, so that the production cost is reduced, and the novel method is suitable for industrialized production.